AAP
FATE icon

Arax Advisory Partners’s Fate Therapeutics FATE Stock Holding History

Arax Advisory Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
44,322
+43,557
+5,694% +$80.6K ﹤0.01% 2601
2026
Q1 		$918 Buy
+765
New +$931 ﹤0.01% 3319
2025
Q4 		– Sell
-8,570
Closed -$10.8K – 4229
2025
Q3 		$10.8K Buy
+8,570
New +$9.24K ﹤0.01% 2562
2024
Q4 		– Sell
-102
Closed -$357 – 2523
2024
Q3 		$357 Hold
102
– – ﹤0.01% 2450
2024
Q2 		$335 Buy
+102
New +$447 ﹤0.01% 2382

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arax Advisory Partners's FATE Position: Q2 2026 in Review

Arax Advisory Partners increased its Fate Therapeutics (FATE) stake by 5,694% in Q2 2026, buying an estimated $80.6K and bringing the position to 44,322 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #2601.

Arax Advisory Partners first reported a position in FATE in Q2 2024 and has held it in 5 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Arax Advisory Partners held 44,322 shares of Fate Therapeutics worth $120K as of Q2 2026.
  • Arax Advisory Partners bought 43,557 Fate Therapeutics shares in Q2 2026, an estimated $80.6K.
  • Fate Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2601 holding.
  • Arax Advisory Partners first reported a position in Fate Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.